GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Talecris IPO addendum:

One aspect of the IPO I didn’t cover in the prior post is this: Why do Talecris’ investors want to cash out now?

Maybe it’s because they recognize that the advent of transgenics will render drugs derived from plasma fractionation obsolete. The quote from Bruce Carter of ZGEN in #msg-17114738 is apropos here.